(Q24201595)

non-alcoholic fatty liver

inferred from title

1 reference

non-alcoholic steatohepatitis

inferred from title

1 reference

1 reference

3

0 references

Siavosh Nasseri-Moghaddam

4

Siavosh Nasseri-Moghaddam

0 references

Layli Eslami

1

Layli Eslami

0 references

Shahin Merat

2

Shahin Merat

0 references

Hermineh Aramin

5

Cochrane Database of Systematic Reviews

Hermineh Aramin

0 references

publication date

27 December 2013

0 references

published in

0 references

cites work

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients w

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Targeting vascular risk in patients with metabolic syndrome but without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Risk for myopathy with statin therapy in high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Nonalcoholic steatohepatitis: definition and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Nonalcoholic steatohepatitis: pathologic features and differential diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Pathology of fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Abnormalities of lipid metabolism in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Hepatology may have problems with putative surrogate outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Significant correlations between severe fatty liver and risk factors for metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Structural mechanism for statin inhibition of HMG-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Risks associated with statin therapy: a systematic overview of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Nonalcoholic steatohepatitis: a study of 49 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Words without action? The production, dissemination, and impact of consensus recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Industry sponsorship and research outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

A lipidomic analysis of nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

CT and MRI of diffuse liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

The utility of radiological imaging in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Statins for the primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Efficacy and long-term adverse effect pattern of lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Statins for acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Pathology of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Inhibitors of Cholesterol Biosynthesis Increase Hepatic Low-Density Lipoprotein Receptor Protein Degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

7 January 2021

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

7 January 2021

Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

7 January 2021

Nonalcoholic steatohepatitis: An expanded clinical entity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

7 January 2021

Rosuvastatin: a safe and effective treatment for dyslipidaemia associated with non-alcoholic steatohepatitis (NASH)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

7 January 2021

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

7 January 2021

Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

7 January 2021

Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008623.PUB2

7 January 2021

10.1002/14651858.CD008623.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

2962514

2962514

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference